PRESS-RELEASE ·Filed Mar 5, 2026

EVAX

Evaxion
NEUTRAL
Impact 3/10
Horizonimmediate Processed7mo ago WireGlobeNewswire
Press release: announcement
Actionable Insight • Neutral

Traders should monitor the rescheduled call for any updates on clinical progress, funding, or pipeline developments. The delay itself is not material, but the subsequent report may contain actionable data.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d ⚠ clustered
EVAX ▲ +14.71% at T+60d
NEUTRAL call ✓ call won +14.71% · α vs SPY +3.41% · entry $3.40 → $3.90
Entry anchored
Mar 4, 03:29 PM ET
via exchange tick
T+1d
-5.29%
call -5.29% · α -3.98%
$3.22
settled 7mo ago
T+5d
+22.94%
call +22.94% · α +25.18%
$4.18
settled 7mo ago
T+20d
+11.18%
call +11.18% · α +14.97%
$3.78
settled 6mo ago
T+60d
+14.71%
call +14.71% · α +3.41%
$3.90
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

Evaxion delayed the filing and publication of its 2025 annual report due to technical issues with external vendors, not related to the content of the report. As a result, the earnings conference call has been rescheduled to March 6, 2026. The company emphasized that the delay is administrative and does not reflect any issues with financial or operational results.

Key Facts

  • Evaxion delayed the release of its 2025 annual report due to technical issues with external regulatory filing vendors.
  • The delay is administrative and unrelated to the report's content.
  • The earnings conference call was rescheduled from March 5 to March 6, 2026, at 8:30 AM ET.
  • Investors must register in advance to participate in the call and receive a PIN.
  • The webcast will be available live and recorded on the company’s website.

Financial Impact

No immediate financial impact — delay is technical and temporary.

Risk Factors

  • Perception risk: Repeated delays or technical issues could raise concerns about operational reliability.
  • Information asymmetry: Material news might be delayed until the report is published.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3250121
36 reports for EVAX
Performance horizon
100% Hit rate 9 of 9 directional calls best @ T+5▲ +22.94%Mar 5, 2026
Filters
Rows
Reports for EVAX — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
6-K
NEUTRAL ★ 3/10
$3.07 $3.21▲ +4.56%▲ +4.45%$3.21 (+4.63%)
Sep 4, 2026
28d ago
6-K
BEARISH ★ 5/10
$3.12 $3.07▲ +1.60%▲ +0.39%$3.21 (−2.96%)
Aug 20, 2026
6w ago
6-K
NEUTRAL ★ 4/10
$3.28 $3.15▼ −3.96%▼ −5.08%$3.21 (−2.07%)
Aug 20, 2026
6w ago
Press Release
NEUTRAL ★ 4/10
$3.28 $3.15▼ −3.96%▼ −5.08%$3.21 (−2.07%)
Aug 17, 2026
6w ago
6-K
NEUTRAL ★ 4/10
$3.13 $3.40▲ +8.63%▲ +9.82%$3.21 (+2.63%)
Aug 14, 2026
7w ago
6-K
NEUTRAL ★ 2/10
$3.34 $3.31▼ −0.90%▲ +0.47%$3.21 (−3.83%)
Aug 14, 2026
7w ago
Press Release
NEUTRAL ★ 2/10
$3.34 $3.31▼ −0.90%▲ +0.47%$3.21 (−3.83%)
Jul 17, 2026
11w ago
6-K
BULLISH ★ 7/10
$3.08 $3.05▼ −0.81%▼ −0.13%$3.21 (+4.46%)
Jul 17, 2026
11w ago
Press Release
NEUTRAL ★ 4/10
$3.08 $3.05▼ −0.81%▼ −0.13%$3.21 (+4.46%)
Jul 13, 2026
11w ago
6-K
NEUTRAL ★ 3/10
$3.02 $3.08▲ +1.82%▲ +2.61%$3.21 (+6.36%)
Showing 10 of 36

US Market Status

Market Open — Closes in 44m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Mar 5, 2026